Literature DB >> 15285010

Drug therapy for ulcerative colitis.

Chang-Tai Xu1, Shu-Yong Meng, Bo-Rong Pan.   

Abstract

Ulcerative colitis (UC) is an inflammatory destructive disease of the large intestine occurred usually in the rectum and lower part of the colon as well as the entire colon. Drug therapy is not the only choice for UC treatment and medical management should be as a comprehensive whole. Azulfidine, Asacol, Pentasa, Dipentum, and Rowasa all contain 5-aminosalicylic acid (5-ASA), which is the topical anti-inflammatory ingredient. Pentasa is more commonly used in treating Crohn's ileitis because Pentasa capsules release more 5-ASA into the small intestine than Asacol tablets. Pentasa can also be used for treating mild to moderate UC. Rowasa enemas are safe and effective in treating ulcerative proctitis and proctosigmoiditis. The sulfa-free 5-ASA agents (Asacol, Pentasa, Dipentum and Rowasa) have fewer side effects than sulfa-containing Azulfidine. In UC patients with moderate to severe disease and in patients who failed to respond to 5-ASA compounds, systemic (oral) corticosteroids should be used. Systemic corticosteroids (prednisone, prednisolone, cortisone, etc.) are potent and fast-acting drugs for treating UC, Crohn's ileitis and ileocolitis. Systemic corticosteroids are not effective in maintaining remission in patients with UC. Serious side effects can result from prolonged corticosteroid treatment. To minimize side effects, corticosteroids should be gradually reduced as soon as the disease remission is achieved. In patients with corticosteroid-dependent or unresponsive to corticosteroid treatment, surgery or immunomodulator is considered. Immunomodulators used for treating severe UC include azathioprine/6-MP, methotrexate, and cyclosporine. Integrated traditional Chinese and Western medicine is safe and effective in maintaining remission in patients with UC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285010      PMCID: PMC4576279          DOI: 10.3748/wjg.v10.i16.2311

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

Review 1.  Update in medical therapy of ulcerative colitis: a practical approach.

Authors:  Seymour Katz
Journal:  J Clin Gastroenterol       Date:  2002-04       Impact factor: 3.062

Review 2.  The state of the art in the management of inflammatory bowel disease.

Authors:  Stephen B Hanauer; Daniel H Present
Journal:  Rev Gastroenterol Disord       Date:  2003

Review 3.  Collagenous colitis evolving into ulcerative colitis: a case report and review of the literature.

Authors:  Bashar Aqel; Michele Bishop; Murli Krishna; John Cangemi
Journal:  Dig Dis Sci       Date:  2003-12       Impact factor: 3.199

4.  Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study.

Authors:  Bente Nørgård; Erzsebet Puho; Lars Pedersen; Andrew E Czeizel; Henrik T Sørensen
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

5.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

6.  Outcome of a conservative approach in severe ulcerative colitis.

Authors:  M Daperno; R Sostegni; N Scaglione; E Ercole; C Rigazio; R Rocca; A Pera
Journal:  Dig Liver Dis       Date:  2004-01       Impact factor: 4.088

Review 7.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  L Sutherland; J K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2003

8.  Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County.

Authors:  Karen Vanessa Winther; Tine Jess; Ebbe Langholz; Pia Munkholm; Vibeke Binder
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

9.  Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.

Authors:  O Schröder; I Blumenstein; A Schulte-Bockholt; J Stein
Journal:  Aliment Pharmacol Ther       Date:  2004-02-01       Impact factor: 8.171

Review 10.  Clinical utility of thiopurine S-methyltransferase genotyping.

Authors:  Hèctor Corominas; Montserrat Baiget
Journal:  Am J Pharmacogenomics       Date:  2004
View more
  23 in total

1.  Manipulation of enteric flora in ulcerative colitis.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

2.  Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis.

Authors:  David C Montrose; Nicole A Horelik; James P Madigan; Gary D Stoner; Li-Shu Wang; Richard S Bruno; Hea Jin Park; Charles Giardina; Daniel W Rosenberg
Journal:  Carcinogenesis       Date:  2010-11-23       Impact factor: 4.944

3.  Red wine polyphenol extract efficiently protects intestinal epithelial cells from inflammation via opposite modulation of JAK/STAT and Nrf2 pathways.

Authors:  Carla Nunes; Natércia Teixeira; Diana Serra; Víctor Freitas; Leonor Almeida; João Laranjinha
Journal:  Toxicol Res (Camb)       Date:  2015-10-05       Impact factor: 3.524

4.  Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract.

Authors:  Elangovan Gopal; Seiji Miyauchi; Pamela M Martin; Sudha Ananth; Penny Roon; Sylvia B Smith; Vadivel Ganapathy
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 5.  Management of inflammatory bowel diseases in Eastern Europe.

Authors:  L Lakatos; P L Lakatos
Journal:  Postgrad Med J       Date:  2006-04       Impact factor: 2.401

6.  Epidemiology and gene markers of ulcerative colitis in the Chinese.

Authors:  Jun Yun; Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

7.  Clinical manifestations and outcomes in severe ulcerative colitis.

Authors:  Xuesong Yang; Wei Yao; Wenbin Liu; Jun Li; Yumin Lu
Journal:  Front Med China       Date:  2007-05

8.  Preventive effect of a pectic polysaccharide of the common cranberry Vaccinium oxycoccos L. on acetic acid-induced colitis in mice.

Authors:  Sergey V Popov; Pavel A Markov; Ida-R Nikitina; Sergey Petrishev; Vasily Smirnov; Yury S Ovodov
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report.

Authors:  Seyed-Amir Mirbagheri; Behtash-Ghazi Nezami; Solmaz Assa; Mannan Hajimahmoodi
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

10.  Unconjugated Bilirubin Attenuates DSS-Induced Colitis Potentially via Enhancement of Bilirubin Reabsorption.

Authors:  Chong Zhao; Hongli Huang; Qiuhua Pan; Wenqi Huang; Wu Peng; Haoming Xu; Zhiqiang Feng; Yanlei Du; Yuqiang Nie; Yongjian Zhou
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.